Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 2/20 | 0.61 |
| ▸ | FNTA | P49354 | 3/20 | 0.58 |
| ▸ | FNTB | P49356 | 3/20 | 0.58 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.58 |
| ▸ | MME | P08473 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29769731 | 0.99 | LTA4H (0.60) | LTA4HFNTAFNTBPGGT1BMME | |
| SCHEMBL30917374 | 0.96 | FNTA (0.56) | LTA4HFNTAFNTBPGGT1BKMT2A | |
| SCHEMBL30051749 | 0.96 | FNTA (0.61) | LTA4HFNTAFNTBPGGT1BKMT2A | |
| SCHEMBL29714758 | 0.93 | LTA4H (0.53) | LTA4HFNTAFNTBPGGT1BMME | |
| SCHEMBL30051273 | 0.92 | FNTA (0.63) | LTA4HFNTAFNTBPGGT1BKMT2A | |
| SCHEMBL21467153 | 0.92 | FNTA (0.55) | LTA4HFNTAFNTBPGGT1BMME | |
| SCHEMBL16430978 | 0.91 | LTA4H (0.58) | LTA4HFNTAFNTBPGGT1BMME | |
| SCHEMBL16430977 | 0.91 | LTA4H (0.58) | LTA4HFNTAFNTBPGGT1BMME | |
| SCHEMBL30051234 | 0.91 | FNTA (0.58) | LTA4HFNTAFNTBPGGT1B | |
| SCHEMBL30051757 | 0.91 | FNTA (0.59) | LTA4HFNTAFNTBPGGT1BMME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | BRANDEIS UNIVERSITY (US) | 2026-05-12 | — | — | US | disclosed |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-08 | — | — | US | disclosed |
| US-10442834-B2 | Deprotection method | AJINOMOTO CO., INC. (JP) | 2019-10-15 | — | — | US | disclosed |
| US-20160024143-A1 | DEPROTECTION METHOD | AJINOMOTO CO., INC. (JP) | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10442834-B2 | Deprotection method | CBR1, AOX1, AOC2 | LTA4H 2049/4885FNTA 2685/4885FNTB 3018/4885 |
| US-12622975-B2 | Peptide-conjugated prodrugs | PEPD, PAM, VIP | LTA4H 3533/4885FNTA 734/4885FNTB 479/4885 |
| US-20160024143-A1 | DEPROTECTION METHOD | CBR1, AOX1, AOC2 | LTA4H 2049/4885FNTA 2685/4885FNTB 3018/4885 |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | VIP, DNPEP, PEPD | LTA4H 1299/4885FNTA 776/4885FNTB 452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.